Tissue matrices comprising placental stem cells

• US 8,435,788 B2
• Filed: 06/24/2010
• Issued: 05/07/2013
• Est. Priority Date: 02/14/2001
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US12/823,063
• Publication Number:
  US 20100260847A1
• Time in Patent Office: 1,048 Days
• Field of Search: None
• US Class Current: 435/395
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61L 2430/34 for soft tissue reconstruction
• CPC Class Codes: A61L 27/3695 characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this A61L27/3687, A61L27/3691 take precedence
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2513/00 3D culture
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0678 Stem cells; Progenitor cells; Precursor cells

Abstract

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Claims

1. A tissue matrix comprising isolated CD34⁻

, CD10⁺, SH2⁺ placental stem cells, wherein said tissue matrix is synthetic.

2. The tissue matrix of claim 1 wherein said placental stem cells are additionally CD90⁺ or CD45⁻

.

3. The tissue matrix of claim 2 wherein said placental stem cells are additionally CD90⁺ and CD45⁻

.

4. The tissue matrix of claim 1 wherein said placental stem cells are additionally one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺.

5. The tissue matrix of claim 4 wherein said placental stem cells are additionally one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺.

6. The tissue matrix of claim 4 wherein said placental stem cells are CD44⁺.

7. The tissue matrix of claim 5 wherein said placental stem cells are CD44⁺.

8. The tissue matrix of claim 1, wherein said placental stem cells are additionally MHC Class II⁻

.

9. The tissue matrix of claim 1 wherein said placental stem cells are tissue culture plastic adherent.

10. The tissue matrix of claim 1, wherein said placental stem cells are additionally one or more of CD29⁺, CD45⁻

, CD90⁺, SH3⁺, SH4⁺, or MHC Class II⁻

.

11. The tissue matrix of claim 10, wherein said placental stem cells are additionally each of CD29⁺, CD45⁻

, CD90⁺, SH3⁺, SH4⁺, and MHC Class II⁻

.

12. A method of making a tissue matrix, comprising seeding isolated CD34⁻

, CD 10⁺, SH2⁺ placental stem cells onto a synthetic tissue matrix, wherein said plcental stem cells are from a human placenta that has been drained of cord blood.

13. The method of claim 12 wherein said placental stem cells are additionally CD90⁺ or CD45⁻

.

14. The method of claim 13 wherein said placental stem cells are additionally CD90⁺ and CD45⁻

.

15. The method of claim 12 wherein said placental stem cells are additionally one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺.

16. The method of claim 13 wherein said placental stem cells are additionally one or more of CD29⁺, CD38⁻

, CD44⁺, CD54⁺, SH3⁺ or SH4⁺.

17. The method of claim 13 wherein said placental stem cells are CD44⁺.

18. The method of claim 14 wherein said placental stem cells are CD44⁺.

19. The method of claim 12, wherein said placental stem cells are additionally MHC Class II⁻

.

20. The method of claim 12 wherein said placental stem cells are tissue culture plastic adherent.

21. The method of claim 12, wherein said placental stem cells are additionally one or more of CD29⁺, CD45⁻

, CD90⁺, SH3⁺, SH4⁺, or MHC Class II⁻

.

22. The method of claim 21, wherein said placental stem cells are additionally each of CD29⁺, CD45⁻

, CD90⁺, SH3⁺, SH4⁺, and MHC Class II⁻

.